参考文献: [1] Li J, Gao J, Liu A, et al. Chinese Children's Leukemia Group. Homoharringtonine-Based Induction Regimen Improved the Remission Rate and Survival Rate in Chinese Childhood AML: A Report From the CCLG-AML 2015...
Improved Survival Rates Among Acute Myeloid Leukemia (AML) Patients 65 to 74 Years: Population-Based Estimates Over Three Decades,Mya S TheinAhmedin JemalMaria R. BaerWilliam B ErshlerJerome W Yates
1. 2023ASH: 2896 Compared to Venetoclax Plus Hypomethylating Agents, High Dose Cytarabine Based Intensive Chemotherapy Induction for Newly Diagnosed Acute Myeloid Leukemia (AML) Leads to a Faster Remission Resulting in Better Survival. 2...
参考文献 [1] Arthur C, Jeffrey A, Yip E, Katsioulas V, et al. Prolonged administration of low-dose cytarabine and thioguanine in elderly patients with acute myeloid leukaemia (AML) achieves high complete remission rates and prolonged survival. Leuk Lymphoma. 2020 Apr;61(4):831-839. [2] ...
With the development of science and technology, the treatment of leukemia has been made great progress, but the cure of the disease is still unsolved, and the 5-year survival rate is only 25%3,4,5,6,7. Although AML patients after treatment, the condition has been greatly improved, but ...
理论上讲,Hubbell的疫苗技术可以击溃一切肿瘤,真正实现"一物降万病魔"的宏愿。参考文献：Slezak, A. J., et al. (2024). Cysteine-binding adjuvant enhances survival and promotes immune function in a murine model of acute myeloid leukemia. Blood Advances. doi.org/10.1182/bloodadvances.2023012529.
AML中国诊疗指南AML部分.ppt,非移植患者10年生存率达37% N=202 43% 37% 总生存概率 1.0 0.8 0.6 0.4 0.2 0.0 时间 (年) 0 2 4 6 8 10 12 14 Eur J Haematol 2007; 78(6):477-486. 目前三十一页\总数五十五页\编于十点 非移植患者10年无复发生存率达32% N=195 40% 32% 无复发
图2A-D.新诊断的AML患者中与总存活率(overall survival) 有关的孩i RNA。通过微阵列检测的具有高或低miR-20(图2A)和 miR-25(图2B)表达的122位AML患者的总存活率的Kaplan-Meier估 计值。使用时序检验(log-rank test )来对比存活曲线之间的差异。 使用不同的技术(miRNA qRT-PCR),使用具有类似临床特征(图4...
Norsworthy KJ, Gao X, Ko CW, et al. Response Rate, Event-Free Survival, and Overall Survival in Newly Diagnosed Acute Myeloid Leukemia: US Food and Drug Administration Trial-Level and Patient-Level Analyses [published ...
CD123与AML患者预后不良及复发密切相关, 是AML细胞及白血病干细胞(leukemia stem cell, LSC)表面特异性的抗原, 这为研发针对CD123靶向治疗的抗体药物奠定了理论基础。 Flotetuzumab作为靶向CD3和CD123的双特异性抗体, 目前在急性白血病...